Annual CFI
-$502.52 M
-$709.21 M-343.13%
December 31, 2023
Summary
- As of February 7, 2025, MDGL annual cash flow from investing activities is -$502.52 million, with the most recent change of -$709.21 million (-343.13%) on December 31, 2023.
- During the last 3 years, MDGL annual CFI has fallen by -$662.30 million (-414.51%).
- MDGL annual CFI is now -343.13% below its all-time high of $206.69 million, reached on December 31, 2022.
Performance
MDGL Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$202.39 M
-$80.29 M-65.76%
September 30, 2024
Summary
- As of February 7, 2025, MDGL quarterly cash flow from investing activities is -$202.39 million, with the most recent change of -$80.29 million (-65.76%) on September 30, 2024.
- Over the past year, MDGL quarterly CFI has dropped by -$80.29 million (-65.76%).
- MDGL quarterly CFI is now -306.41% below its all-time high of $98.05 million, reached on March 31, 2024.
Performance
MDGL Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$588.56 M
-$252.59 M-75.18%
September 30, 2024
Summary
- As of February 7, 2025, MDGL TTM cash flow from investing activities is -$588.56 million, with the most recent change of -$252.59 million (-75.18%) on September 30, 2024.
- Over the past year, MDGL TTM CFI has dropped by -$252.59 million (-75.18%).
- MDGL TTM CFI is now -384.76% below its all-time high of $206.69 million, reached on December 31, 2022.
Performance
MDGL TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
MDGL Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -343.1% | -65.8% | -75.2% |
| 3 y3 years | -414.5% | -65.8% | -75.2% |
| 5 y5 years | -32.2% | -65.8% | -75.2% |
MDGL Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -343.1% | at low | -306.4% | +44.1% | -384.8% | at low |
| 5 y | 5-year | -343.1% | at low | -306.4% | +44.1% | -384.8% | at low |
| alltime | all time | -343.1% | at low | -306.4% | +44.1% | -384.8% | at low |
Madrigal Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$202.39 M(+65.8%) | -$588.56 M(+75.2%) |
| Jun 2024 | - | -$122.10 M(-224.5%) | -$335.97 M(+54.4%) |
| Mar 2024 | - | $98.05 M(-127.1%) | -$217.60 M(-56.7%) |
| Dec 2023 | -$502.52 M(-343.1%) | -$362.12 M(-821.4%) | -$502.52 M(+579.0%) |
| Sep 2023 | - | $50.20 M(-1445.1%) | -$74.01 M(+25.3%) |
| Jun 2023 | - | -$3.73 M(-98.0%) | -$59.07 M(+63.6%) |
| Mar 2023 | - | -$186.86 M(-381.5%) | -$36.10 M(-117.5%) |
| Dec 2022 | $206.69 M(-4188.7%) | $66.39 M(+1.9%) | $206.69 M(+32.5%) |
| Sep 2022 | - | $65.14 M(+238.6%) | $155.94 M(+19.1%) |
| Jun 2022 | - | $19.24 M(-65.6%) | $130.90 M(+55.2%) |
| Mar 2022 | - | $55.93 M(+257.5%) | $84.33 M(-1768.3%) |
| Dec 2021 | -$5.05 M(-103.2%) | $15.64 M(-61.0%) | -$5.05 M(-80.2%) |
| Sep 2021 | - | $40.09 M(-246.7%) | -$25.50 M(-187.4%) |
| Jun 2021 | - | -$27.32 M(-18.3%) | $29.17 M(-61.6%) |
| Mar 2021 | - | -$33.46 M(+597.5%) | $75.86 M(-52.5%) |
| Dec 2020 | $159.78 M(+420.3%) | -$4.80 M(-105.1%) | $159.78 M(+19.2%) |
| Sep 2020 | - | $94.75 M(+389.3%) | $134.07 M(+98.4%) |
| Jun 2020 | - | $19.36 M(-61.6%) | $67.58 M(-20.2%) |
| Mar 2020 | - | $50.46 M(-265.4%) | $84.66 M(+175.7%) |
| Dec 2019 | $30.71 M(-108.1%) | -$30.51 M(-207.9%) | $30.71 M(-64.4%) |
| Sep 2019 | - | $28.27 M(-22.4%) | $86.20 M(-152.5%) |
| Jun 2019 | - | $36.44 M(-1143.8%) | -$164.09 M(-41.7%) |
| Mar 2019 | - | -$3.49 M(-114.0%) | -$281.44 M(-26.0%) |
| Dec 2018 | -$380.08 M(+1627.1%) | $24.99 M(-111.3%) | -$380.08 M(-4.7%) |
| Sep 2018 | - | -$222.03 M(+174.4%) | -$398.98 M(+105.8%) |
| Jun 2018 | - | -$80.91 M(-20.8%) | -$193.84 M(+70.7%) |
| Mar 2018 | - | -$102.12 M(-1778.3%) | -$113.57 M(+416.1%) |
| Dec 2017 | -$22.01 M(-200.1%) | $6.08 M(-136.0%) | -$22.01 M(+22.2%) |
| Sep 2017 | - | -$16.89 M(+2509.9%) | -$18.01 M(-267.0%) |
| Jun 2017 | - | -$647.00 K(-93.9%) | $10.79 M(-5.7%) |
| Mar 2017 | - | -$10.56 M(-204.8%) | $11.44 M(-48.0%) |
| Dec 2016 | $21.99 M(>+9900.0%) | $10.08 M(-15.4%) | $21.99 M(+84.6%) |
| Sep 2016 | - | $11.91 M(>+9900.0%) | $11.91 M(-19.0%) |
| Jun 2016 | - | $0.00(0.0%) | $14.70 M(-276.8%) |
| Mar 2016 | - | $0.00(0.0%) | -$8.32 M(<-9900.0%) |
| Dec 2015 | $0.00 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sep 2015 | - | $14.70 M(-163.9%) | -$930.00 K(-98.2%) |
| Jun 2015 | - | -$23.02 M(-376.8%) | -$51.21 M(+206.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | $8.32 M(-994.3%) | -$16.72 M(+89.2%) |
| Dec 2014 | -$8.84 M(-64.2%) | -$930.00 K(-97.4%) | -$8.84 M(-61.7%) |
| Sep 2014 | - | -$35.58 M(-410.0%) | -$23.06 M(-209.7%) |
| Jun 2014 | - | $11.48 M(-29.1%) | $21.02 M(-25.4%) |
| Mar 2014 | - | $16.20 M(-206.9%) | $28.16 M(-214.2%) |
| Dec 2013 | -$24.65 M(+147.9%) | -$15.15 M(-278.4%) | -$24.65 M(+726.4%) |
| Sep 2013 | - | $8.49 M(-54.4%) | -$2.98 M(-83.7%) |
| Jun 2013 | - | $18.62 M(-150.9%) | -$18.32 M(-44.9%) |
| Mar 2013 | - | -$36.62 M(-661.6%) | -$33.24 M(+234.3%) |
| Dec 2012 | -$9.94 M(-206.6%) | $6.52 M(-195.3%) | -$9.94 M(-382.2%) |
| Sep 2012 | - | -$6.84 M(-285.0%) | $3.52 M(-79.4%) |
| Jun 2012 | - | $3.70 M(-127.8%) | $17.07 M(-2260.9%) |
| Mar 2012 | - | -$13.32 M(-166.6%) | -$790.00 K(-108.5%) |
| Dec 2011 | $9.33 M(-147.1%) | $19.99 M(+198.0%) | $9.33 M(-183.8%) |
| Sep 2011 | - | $6.71 M(-147.4%) | -$11.14 M(-64.2%) |
| Jun 2011 | - | -$14.16 M(+342.3%) | -$31.08 M(+35.1%) |
| Mar 2011 | - | -$3.20 M(+567.1%) | -$23.00 M(+16.2%) |
| Dec 2010 | -$19.80 M(-194.1%) | -$480.00 K(-96.4%) | -$19.80 M(+752.8%) |
| Sep 2010 | - | -$13.24 M(+117.5%) | -$2.32 M(-110.3%) |
| Jun 2010 | - | -$6.09 M(<-9900.0%) | $22.59 M(-48.1%) |
| Mar 2010 | - | $0.00(-100.0%) | $43.52 M(+106.7%) |
| Dec 2009 | $21.05 M(-188.9%) | $17.00 M(+45.6%) | $21.05 M(-215.6%) |
| Sep 2009 | - | $11.68 M(-21.3%) | -$18.20 M(-40.0%) |
| Jun 2009 | - | $14.84 M(-166.1%) | -$30.32 M(-33.7%) |
| Mar 2009 | - | -$22.47 M(+1.0%) | -$45.76 M(+93.2%) |
| Dec 2008 | -$23.69 M(-319.6%) | -$22.25 M(+4911.7%) | -$23.69 M(+929.4%) |
| Sep 2008 | - | -$444.00 K(-25.5%) | -$2.30 M(-8.6%) |
| Jun 2008 | - | -$596.00 K(+50.9%) | -$2.52 M(+101.0%) |
| Mar 2008 | - | -$395.00 K(-54.4%) | -$1.25 M(-111.6%) |
| Dec 2007 | $10.79 M(-54.3%) | -$866.00 K(+31.2%) | $10.79 M(-7.4%) |
| Sep 2007 | - | -$660.00 K(-198.7%) | $11.65 M(-5.4%) |
| Jun 2007 | - | $669.00 K(-94.3%) | $12.31 M(+5.7%) |
| Mar 2007 | - | $11.64 M(-630.1%) | $11.64 M(-630.1%) |
| Dec 2006 | $23.57 M(-39.8%) | - | - |
| Dec 2005 | $39.18 M(-189.4%) | - | - |
| Mar 2005 | - | -$2.20 M | -$2.20 M |
| Dec 2004 | -$43.81 M(+8.4%) | - | - |
| Dec 2003 | -$40.40 M | - | - |
FAQ
- What is Madrigal Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual CFI year-on-year change?
- What is Madrigal Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly CFI year-on-year change?
- What is Madrigal Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals TTM CFI year-on-year change?
What is Madrigal Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of MDGL is -$502.52 M
What is the all time high annual CFI for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual cash flow from investing activities is $206.69 M
What is Madrigal Pharmaceuticals annual CFI year-on-year change?
Over the past year, MDGL annual cash flow from investing activities has changed by -$709.21 M (-343.13%)
What is Madrigal Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of MDGL is -$202.39 M
What is the all time high quarterly CFI for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly cash flow from investing activities is $98.05 M
What is Madrigal Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, MDGL quarterly cash flow from investing activities has changed by -$80.29 M (-65.76%)
What is Madrigal Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of MDGL is -$588.56 M
What is the all time high TTM CFI for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high TTM cash flow from investing activities is $206.69 M
What is Madrigal Pharmaceuticals TTM CFI year-on-year change?
Over the past year, MDGL TTM cash flow from investing activities has changed by -$252.59 M (-75.18%)